GODAVARI-BIOREFINERIES
10.6.2024 13:11:26 CEST | Business Wire | Press release
A new specialty biochemical plant has been inaugurated at the Sakarwadi manufacturing facility in Maharashtra, India where Godavari Biorefineries Limited (GBL) intends to produce biobased chemicals to support the green and net-zero ambitions of its clientele in different markets across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240607431453/en/
Inauguration of new specialty biochemical plant at the Sakarwadi manufacturing facility in Maharashtra, India (Photo: Business Wire)
GBL has taken a next step with the intention to support the world’s ambition for net-zero strategies by developing a multi-purpose plant which aims to produce biobased chemicals for coatings & resins, cosmetics, pharmaceuticals and food & fragrances markets.
“At GBL we make Specialty Chemicals from Renewable Resources using Green Chemistry. We work with farmers to develop sustainable agricultural value chains that serve as a feedstock for our biobased chemicals,” said Samir Somaiya, Chairman of Somaiya Group and Godavari Biorefineries Ltd.
This multi-purpose plant is one of the steps GBL has taken to support and partner with leading companies to enlarge the amount of biobased chemical blocks in the chemical industry for different markets and products, and intends to produce biochemicals like biobutanol, biobased ethers and esters in this plant. GBL has the strategy to further develop and scale-up its capacity in the coming years in volumes and for new biobased chemicals.
“We work in close relation and collaboration with our customers to develop and produce new biobased chemical building blocks in several markets. In co-creation we work from R&D to pilot scale towards the (semi-)commercial scale of new biobased chemicals into several applications and products that can become biobased and green. It is a journey towards net-zero where we are open for new partnerships and new insights, and define pathways to take together,” said Sangeeta Srivastava, CEO of Godavari Biorefineries Ltd.
GBL is a flagship company of the diversified Somaiya group with an experience of over eight decades in the sugar industry and over six decades in the biobased chemicals industry. We work with our farmers in sugarcane and other biomass crops to create value for their communities and our customers' value chains.
Padma Vibhushan Prof. M. M. Sharma, a luminary in the field of chemical engineering, performed the ribbon-cutting ceremony and delivered an inspiring address. He highlighted the critical role of R&D in the chemical industry and complimented GBL efforts in establishing a plant that represents the future of specialty chemicals manufacturing.
For information please visit: http://godavaribiorefineries.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240607431453/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 08:00:00 CEST | Press release
Endotronix co-founder and former CEO joins VahatiCor as the company advances the A-FLUX Reducer System® and the SERRA-I early feasibility study VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom